The Inflation Reduction Act (IRA) established Medicare's Maximum Fair Price (MFP) program, with negotiated prices taking effect for the first 10 Medicare Part D drugs on January 1, 2026, and an additional 15 drugs on January 1, 2027.
Separately, the 340B Rebate Model Pilot is scheduled to begin January 1, 2027, allowing participating manufacturers with approved plans to provide 340B discounts through rebates rather than upfront pricing for certain eligible drugs
These significant changes present considerable operational challenges for Covered Entities.
To address these transitions, Tungsten+PLUS™ is designed to support the new 340B Rebate Model, facilitate the implementation of Maximum Fair Price, and improve Dispute Automation to effectively manage the challenges of the 340B program that all stakeholders encounter.
DaysDays
HrsHours
MinsMinutes
SecsSeconds